Consideration of dual characters of exosomes in the tumour immune response

Cell Biology International

Volumn 38, Issue 4, 2014, Pages 538-545

  Bai, Jun ^a   Xie, Xin ^b,c   Lei, Yun ^a   An, Gaili ^a   He, Li ^a   Chen, Ruping ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c Institute of Integrated Medical Information   (China)

Author keywords

Exosome; Immune activation; Immune tolerance; Immunotherapy; Tumourigenesis

Indexed keywords

HEAT SHOCK PROTEIN 70; TUMOR ANTIGEN;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EXOSOME; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; TUMOR IMMUNITY;

EXOSOME; IMMUNE ACTIVATION; IMMUNE TOLERANCE; IMMUNOTHERAPY; TUMOURIGENESIS;

B-LYMPHOCYTES; EXOSOMES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84895894248     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10208     Document Type: Article

References (63)

1. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172: 2126-36.
2. Berenblum I, Shubik P (1947) The role of croton oil applications, associated with a single painting of a carcinogen, in tumour induction of the mouse's skin. Br J Cancer 1: 379-82.
3. Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, Neuberg D, Canning CM, Alyea EP, Soiffer RJ, Brusic V, Ritz J, Wu CJ (2010) Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 70: 906-15.
4. Bu N, Li QL, Feng Q, Sun BZ (2006) Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk Lymphoma 47: 913-8.
5. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27.
6. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L (2004) Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172: 2137-46.
7. Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q, Cao X (2006) Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36: 1598-607.
8. Cho JA, Lee YS, Kim SH, Ko JK, Kim CW (2009) MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett 275: 256-65.
9. Clayton A, Mitchell JP, Court J, MasonMD, Tabi Z (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67: 7458-66.
10. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-58.
11. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113: 3365-74.
12. Federico M (2012) From virus-like particles to engineered exosomes for a new generation of vaccines. Future Virol 7: 473-82.
13. Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, Tanosaki R, Utsunomiya A, Uike N, Yoshida S, Okamura J, Tomonaga M (2005) Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19: 829-34.
14. Guo F, Chang CK, Fan HH, Nie XX, Ren YN, Liu YY, Zhao LH (2008) Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res 36: 1342-53.
15. Hao S, Bai O, Yuan J, Qureshi M, Xiang J (2006a) Dendritic cellderived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 3: 205-11.
16. Hao S, Ye Z, Yang J, Bai O, Xiang J (2006b) Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity. Cancer Biother Radiopharm 21: 146-54.
17. Harding C, Heuser J, Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97: 329-39.
18. Holmberg D, Andersson A, Carlsson L, Forsgren S (1989) Establishment and functional implications of B-cell connectivity. Immunol Rev 110: 89-103.
19. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-89.
20. Johnson-Leger CA, Dean CJ (1994) Presentation of anti-idiotypic antibody is sensitive to ionizing radiation. J Immunol 153: 574-83.
21. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-61.
22. Keller S, Konig AK, Marme F, Runz S, Wolterink S, Koensgen D. Mustea A, Sehouli J, Altevogt P (2009) Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 278: 73-81.
23. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD (2007) MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J Immunol 179: 2235-41.
24. Le RQ, Bevans M, Savani BN, Mitchell SA, Stringaris K, Koklanaris E, Barrett AJ (2010) Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 16: 1162-70.
25. Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K, Szegletes Z, Varo G, Siklos L, Katona RL, Tubak V, Howard OM, Duda E, Minarovits J, Nagy K, Buzas K (2012) Melanoma cellderived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Lett 148: 34-8.
26. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73: 1907-20.
27. Mathivanan S, Simpson RJ (2009) ExoCarta: a compendium of exosomal proteins and RNA. Proteomics 9: 4997-5000.
28. Mignot G, Roux S, Thery C, Segura E, Zitvogel L (2006) Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 10: 376-88.
29. Nash RA, Yunosov M, Abrams K, Hwang B, Castilla-Llorente C, Chen P, Farivar AS, Georges GE, Hackman RC, Lamm WJ, Lesnikova M, Ochs HD, Randolph-Habecker J, Ziegler SF, Storb R, Storer B, Madtes DK, Glenny R, Mulligan MS (2009) Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation. Am J Transplant 9: 1037-47.
30. Onishi H, Morisaki T, Katano M (2012) Immunotherapy approaches targeting regulatory T-cells. Anticancer Res 32: 997-1003.
31. Pan BT, Johnstone RM (1983) Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33: 967-78.
32. Pan BT, Teng K, Wu C, Adam M, Johnstone RM (1985) Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 101: 942-8.
33. Prehn RT (2010) The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. Clin Dev Immunol 2010: 851728.
34. Prehn RT, Prehn LM (2008) The flip side of immune surveillance: immune dependency. Immunol Rev 222: 341-56.
35. Prehn RT, Prehn LM (2012) Is an immune reaction required for malignant transformation and cancer growth? Cancer Immunol Immunother 61: 963-6.
36. Prehn RT, Prehn LM (2013) A new kink in an old theory of carcinogenesis. Theor Biol Med Model 10: 12.
37. Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ, Jiang YH, Yang XH, Liu YP (2009) Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis 41: 875-80.
38. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ (1996) B lymphocytes secrete antigenpresenting vesicles. J Exp Med 183: 1161-72.
39. Ristorcelli E, Beraud E, Mathieu S, Lombardo D, Verine A (2009) Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer 125: 1016-26.
40. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-11.
41. Sheng H, Hassanali S, Nugent C, Wen L, Hamilton-Williams E, Dias P, Dai YD (2011) Insulinoma-released exosomes or microparticles are immunostimulatory and can activate autoreactive T cells spontaneously developed in nonobese diabetic mice. J Immunol 187: 1591-600.
42. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6: 267-83.
43. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L (2006) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33: 369-83.
44. Soderberg A, Barral AM, Soderstrom M, Sander B, Rosen A (2007) Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. Free Radic Biol Med 43: 90-9.
45. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G (2002) The biogenesis and functions of exosomes. Traffic 3: 321-30.
46. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL (2010) Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 5: e11469.
47. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jèze G, Lemonnier F, Zitvogel L (2006) Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176: 2722-9.
48. Taylor DD, Gercel-Taylor C (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92: 305-11.
49. Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-93.
50. Thomas L (1982) On immunosurveillance in human cancer. Yale J Biol Med 55: 329-33.
51. Udono H, Srivastava PK (1993) Heat shock protein 70-associated peptides elicit specific cancer immunity. J ExpMed 178: 1391-6.
52. Udono H, Srivastava PK (1994) Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152: 5398-403.
53. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-9.
54. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66: 9290-8.
55. van Deurs B, Holm PK, Kayser L, Sandvig K, Hansen SH (1993) Multivesicular bodies in HEp-2 cells are maturing endosomes. Eur J Cell Biol 61: 208-24.
56. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL (2009) Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumorreactive activated CD8+ T lymphocytes. J Immunol 183: 3720-30.
57. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303.
58. Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slattery K, Qureshi M, Wei Y, Deng Y, Xiang J (2011) Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med 14: 2655-66.
59. Yang C, Robbins PD (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011: 842849.
60. Yang Y, Xiu F, Cai Z, Wang J, Wang Q, Fu Y, Cao X (2007) Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 133: 389-99.
61. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM (2007) Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 58: 267-74.
62. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, Zhang HG (2007) Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-75.
63. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cellfree vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600.